Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer

Although the combination of chemotherapy and immunotherapy is a hot topic in lung cancer, little is understood regarding the possible mechanisms behind their synergy. Moreover, safety is a major concern for clinicians while performing chemotherapy. Therefore, it is important to determine the appropr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer letters 2021-03, Vol.500, p.163-171
Hauptverfasser: Zhou, Li, Xu, Qiuli, Huang, Litang, Jin, Jiajia, Zuo, Xueying, Zhang, Qun, Ye, Liang, Zhu, Suhua, Zhan, Ping, Ren, Jianan, Lv, Tangfeng, Song, Yong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Although the combination of chemotherapy and immunotherapy is a hot topic in lung cancer, little is understood regarding the possible mechanisms behind their synergy. Moreover, safety is a major concern for clinicians while performing chemotherapy. Therefore, it is important to determine the appropriate dose and period of chemotherapy for combining it with immunotherapy, and investigate the underlying synergistic mechanism. Here, we showed that carboplatin can induce DNA damage and activate the canonical STING/TBK1/IRF3 pathway and non-canonical STING-NF-κB signaling complex. Further, low-dose carboplatin changed the “cold” tumor into a “hot” tumor via the signaling hub STING, augmenting CD8+ T-cell infiltration, increasing PD-L1 expression, and hence potentiating the anti-tumor effect of PD-1 inhibitors; importantly, there were no adverse effects. Furthermore, knocking down STING in tumor cells effectively reversed PD-L1 upregulation and STING pathway activation, and reduced the anti-tumor effect of low-dose carboplatin and carboplatin-PD-1 inhibitor combination. Our findings collectively reported a previously unexplored role of low-dose carboplatin targeting in the STING pathway and provided an economical, useful and safe option for improving the efficacy of PD-1 inhibitors in lung cancer. •Low-dose carboplatin increases CD8+ T cell infiltration and PD-L1 expression.•Low-dose carboplatin is safe and turns a “cold” tumor into a “hot” tumor.•Low-dose carboplatin potentiates the anti-tumor effect of PD-1 inhibitors.•Carboplatin induces DNA Damage and activates the STING signaling pathway.•STING knockdown in tumor reverses the anti-tumor effect of low-dose carboplatin.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2020.11.049